{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:36:36Z","timestamp":1773945396355,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hypotension can occur in patients receiving levodopa (L-dopa) treatment for parkinsonism. However, only few studies have focused on the characteristics of orthostatic hypotension (OH) induced by the L-dopa challenge test (LCT). This study aimed to investigate the characteristics and influencing factors of LCT-induced OH in a relatively large sample of patients with Parkinson\u2019s disease (PD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Seventy-eight patients with PD without a previous diagnosis of OH underwent the LCT. Blood pressure (BP) in the supine and standing positions was measured before and 2 hours after the LCT. If diagnosed with OH, the patients\u2019 BP was monitored again 3 hours after the LCT. The clinical features and demographics of the patients were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eight patients were diagnosed with OH 2 hours after the LCT (median dose of 375\u2009mg L-dopa\/benserazide; incidence = 10.3%). One patient without symptoms had OH 3 hours after the LCT. Compared with patients without OH, patients with OH had lower 1- and 3-minutes standing systolic BP and 1-minute standing diastolic BP at baseline and 2 hours after the LCT. Patients in the OH group were of older age (65.31\u2009\u00b1\u20094.17 years vs 59.74\u2009\u00b1\u20095.55years) and had lower Montreal Cognitive Assessment scores (17.5 vs 24) and higher L-dopa\/benserazide levels (375 [250, 500] mg vs 250 [125, 500] mg). Older age markedly increased the odds of having LCT-induced OH (odds ratio, 1.451; 95% confidence interval, 1.055\u20131.995; <jats:italic toggle=\"yes\">P<\/jats:italic> = .022).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>LCT increased the odds of OH in non-OH PD, causing symptomatic OH in 10.3% of patients in our study, thereby raising safety concerns. Increase in age was observed to be a risk factor for LCT-induced OH in PD patients. A study with a larger sample size is warranted to confirm our results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration number:<\/jats:title>\n            <jats:p>Clinical Trials Registry under ChiCTR2200055707.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Date of registration:<\/jats:title>\n            <jats:p>January 16, 2022.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033161","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T20:03:59Z","timestamp":1677787439000},"page":"e33161","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson\u2019s disease: Results from a single-center trial"],"prefix":"10.1097","volume":"102","author":[{"given":"Dan","family":"Su","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Liangxiang Hospital of Beijing Fangshan District, Beijing, China"},{"name":"National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Liangxiang Hospital of Beijing Fangshan District, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baolei","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-4429","authenticated-orcid":false,"given":"Jagadish K.","family":"Chhetri","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piu","family":"Chan","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Geriatric Diseases, Xuanwu Hospital of Capital Medical University, Beijing, China"},{"name":"Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing Institute of Geriatrics, Beijing, China"},{"name":"Clinical Center for Parkinson\u2019s Disease, Parkinson Disease Center of Beijing Institute for Brain Disorders, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019.","volume":"9","author":"Ou","year":"2021","journal-title":"Front Public Health"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/mds.28762","article-title":"Prevalence of Parkinson\u2019s disease: a community-based study in China.","volume":"36","author":"Qi","year":"2021","journal-title":"Mov Disord"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1474-4422(18)30355-7","article-title":"The burden of Parkinson\u2019s disease: a worldwide perspective.","volume":"17","author":"Rocca","year":"2018","journal-title":"Lancet Neurol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.parkreldis.2011.04.016","article-title":"Prevalence of orthostatic hypotension in Parkinson\u2019s disease: a systematic review and meta-analysis.","volume":"17","author":"Velseboer","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.jamda.2021.07.010","article-title":"Orthostatic hypotension is a risk factor for falls among older adults: 3-year follow-up.","volume":"22","author":"Hohtari-Kivim\u00e4ki","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.autneu.2020.102717","article-title":"Morbidity and mortality in orthostatic hypotension.","volume":"229","author":"Farrell","year":"2020","journal-title":"Auton Neurosci"},{"key":"R7-20250504","first-page":"200","article-title":"Influence of levodopa on orthostatic hypotension in Parkinson\u2019s disease.","volume":"54","author":"Jost","year":"2020","journal-title":"Neurol Neurochir Pol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1468-1331.2007.01672.x","article-title":"Blood pressure and heart rate in parkinsonian patients with and without wearing-off.","volume":"14","author":"Pursiainen","year":"2007","journal-title":"Eur J Neurol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"778856","DOI":"10.3389\/fnagi.2021.778856","article-title":"Effect of acute levodopa up-titration on blood pressure in patients with early stage Parkinson\u2019s disease: results of a levodopa challenge test.","volume":"13","author":"He","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2017.02.007","article-title":"Response of non-motor symptoms to levodopa in late-stage Parkinson\u2019s disease: results of a levodopa challenge test.","volume":"39","author":"Fabbri","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mds.1069","article-title":"Consensus statement on the role of acute dopaminergic challenge in Parkinson\u2019s disease.","volume":"16","author":"Albanese","year":"2001","journal-title":"Mov Disord"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mds.10123","article-title":"Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson\u2019s disease diagnosis.","volume":"17","author":"Merello","year":"2002","journal-title":"Mov Disord"},{"key":"R13-20250504","first-page":"165","article-title":"Parkinson\u2019s Disease Society Brain Bank, London: overview and research.","volume":"39","author":"Daniel","year":"1993","journal-title":"J Neural Transm Suppl"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease.","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson\u2019s disease rating scale: comparison with the unified Parkinson\u2019s disease rating scale.","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov Disord"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0891988711422528","article-title":"Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study.","volume":"24","author":"Lu","year":"2011","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/occmed\/kqv054","article-title":"Hamilton Rating Scale for Anxiety (HAM-A).","volume":"65","author":"Thompson","year":"2015","journal-title":"Occup Med (Lond)"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton depression rating scale.","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J Affect Disord"},{"issue":"suppl 1","key":"R19-20250504","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1007\/PL00007730","article-title":"PDQ-39: a review of the development, validation and application of a Parkinson\u2019s disease quality of life questionnaire and its associated measures.","volume":"245","author":"Peto","year":"1998","journal-title":"J Neurol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2011.08.013","article-title":"Validation of the non-motor symptoms questionnaire (NMS-Quest).","volume":"18","author":"Romenets","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease.","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00415-020-09810-7","article-title":"Levodopa challenge test: indications, protocol, and guide [protocol]. and guide.","volume":"268","author":"Saranza","year":"2021","journal-title":"J Neurol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/WNL.46.5.1470","article-title":"Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology.","volume":"46","year":"1996","journal-title":"Neurology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jns.2017.08.2933","article-title":"Levodopa induced orthostatic hypotension in Parkinson\u2019s disease: a single-dose response study.","volume":"381","author":"Thiankhaw","year":"2017","journal-title":"J Neurol Sci"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1532-5415.1976.tb04296.x","article-title":"Cardiovascular effects of levodopa in aged versus younger patients with Parkinson\u2019s disease.","volume":"24","author":"Wener","year":"1976","journal-title":"J Am Geriatr Soc"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1532-5415.1974.tb05836.x","article-title":"Effects of levodopa therapy in patients with Parkinson\u2019s disease: statistical evidence for reduced tolerance to levodopa in the elderly.","volume":"22","author":"Grad","year":"1974","journal-title":"J Am Geriatr Soc"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/bmj.1.5694.474","article-title":"Hypotension caused by L-dopa.","volume":"1","author":"Calne","year":"1970","journal-title":"Br Med J"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/14740338.2014.888057","article-title":"Risk of heart failure following treatment with dopamine agonists in Parkinson\u2019s disease patients.","volume":"13","author":"Perez-Lloret","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R29-20250504","first-page":"75","article-title":"Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment.","volume":"13","author":"G\u00fcnaydin","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/mds.27958","article-title":"Cardiac noradrenaline turnover and heat shock protein 27 phosphorylation in dyskinetic monkeys.","volume":"35","author":"Almela","year":"2020","journal-title":"Mov Disord"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.parkreldis.2014.04.007","article-title":"Cardiovascular effects of levodopa in Parkinson\u2019s disease.","volume":"20","author":"Noack","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.165.3890.291","article-title":"Renin-aldosterone system in Parkinson\u2019s disease.","volume":"165","author":"Barbeau","year":"1969","journal-title":"Science"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:35:37Z","timestamp":1746326137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033161","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,3]]}}}